22 Results for "

catalepsy

" in MedChemExpress (MCE) Product Catalog:
Products (22)

22 Results for "catalepsy" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-109139
CAS No.: 1337962-47-6
Purity:  99.84%
Synonyms: NIR178; PBF509
Target:  

Adenosine Receptor

Research Areas:  

Neurological Disease Cancer

Taminadenant (NIR178; PBF509) is a highly potent and orally active adenosine A2A receptor (A2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18654
CAS No.: 1235318-89-4
Target:  

mGluR

Research Areas:  

Neurological Disease

ADX88178 is an orally active, blood-brain barrier-penetrant, selective positive allosteric modulator of mGluR4, with an EC50 of 3.5 nM against hmGluR4. ADX88178 modulates mGlu4 activity, enhances glutamate-mediated receptor activation, and increases the apparent affinity of glutamate for the receptor. ADX88178 reverses haloperidol-induced catalepsy, potentiates the effects of levodopa (L-DOPA) and quinpirole, but fails to alleviate established abnormal involuntary movements, does not exacerbate L-DOPA-induced dyskinesia, and does not affect forelimb akinesia when administered alone. ADX88178 can be used in research related to L-DOPA-induced dyskinesia and Parkinson's disease .
loading...
    loading...
Cat. No.: HY-116819
CAS No.: 1638646-27-1
Purity:  ≥98.0%
Target:  

GCGR

VU0453379 is a blood-brain barrier permeable GLP-1R positive allosteric modulator (PAM) with an EC50 value of 1.3 μM. VU0453379 potentiates the actions of endogenous GLP-1 and synthetic peptide agonists, and promotes GLP-1 receptor internalization. VU0453379 stimulates insulin secretion from primary mouse islets. VU0453379 enhances the function of endogenous GLP-1R and reverses catalepsy in animal models. VU0453379 is useful for research on Parkinson's disease and type 2 diabetes .
loading...
    loading...
Cat. No.: HY-113421
CAS No.: 68171-52-8
Purity:  ≥98.0%
Synonyms: Linoleic acid monoethanolamide
Target:  

Cannabinoid Receptor

Research Areas:  

Neurological Disease

Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1(CB1)and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .
loading...
    loading...
Cat. No.: HY-110018
CAS No.: 199875-69-9
Purity:  98.36%
N-Arachidonyldopamine acts as an Anandamide (HY-10863) membrane transport inhibitor, a selective CB1 cannabinoid receptor agonist, and a VR1 receptor activator. It exhibits an EC50 value of 48 nM for rat VR1 and a Ki value of 0.25 μM for CB1. N-Arachidonyldopamine exists in mammalian neural tissues. It stimulates intracellular Ca 2+ mobilization, mediates cannabinoid-like effects, and induces hypothermia, hypomotility, catalepsy, analgesia, and hyperalgesia to heat. N-Arachidonyldopamine possesses anticancer activity against breast cancer. It can be used in research related to breast cancer and heat hyperalgesia .
loading...
    loading...
Cat. No.: HY-113421S
CAS No.: 1451194-69-6
Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide . Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1(CB1)and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .
loading...
    loading...
Cat. No.: HY-149933
CAS No.: 871978-21-1
AM841 is a cannabinoid superagonist and a covalent, irreversible full agonist of CB1. AM841 can activate peripheral CB1 receptors to reduce excitatory neurotransmission and GI smooth muscle contractility, and inhibit synaptic transmission. AM841 is peripherally restricted at low doses in mice, with extremely low brain penetration, potently inhibits gastrointestinal motility, and can reverse acute stress-induced hyperaccelerated gastrointestinal transit; at high doses, it can produce the classic tetrad of central cannabinoid phenotypes (analgesia, catalepsy, hypothermia, decreased spontaneous activity). AM841 can improve intestinal inflammation in mouse colitis models. AM841 induces transient stress-induced hyperthermia. AM841 can be used for research on gastrointestinal motility disorders and colitis .
loading...
    loading...
Cat. No.: HY-14866
CAS No.: 757950-09-7
Synonyms: ADX-10059
Target:  

mGluR

Research Areas:  

Neurological Disease

Raseglurant (ADX-10059) is a mGlu5 receptor negative allosteric modulator. Raseglurant is effective against migraine. Raseglurant reduces the Haloperidol (HY-14538)-induced catalepsy in mice .
loading...
    loading...
Cat. No.: HY-105879
CAS No.: 72808-81-2
Synonyms: HR-592 free base
Target:  

Drug Derivative

Research Areas:  

Neurological Disease

Tepirindole (HR-592 free base) is an orally active Indole (HY-W001132) derivative. Tepirindole reduces incidence of catalepsy induced by Haloperidol (HY-14538). Tepirindole suppresses the turning behavior induced by Methamphetamine .
loading...
    loading...
Cat. No.: HY-178203
CAS No.: 3054511-18-8
Target:  

Cannabinoid Receptor

Research Areas:  

Neurological Disease

AM12814 is a potent and partial CB1 and CB2 agonist with Ki values of 0.7 nM and 3.4 nM. AM12814 can inhibit cAMP accumulation and recruitse β-arrestin 2. AM12814 exhibits cannabimimetic effects. AM12814 can be used for the research of neurological disease, suah as catalepsy .
loading...
    loading...
Cat. No.: HY-B1573A
CAS No.: 36504-94-6
Synonyms: AY-23,028; dl-Butaclamol hydrochloride
(±)-Butaclamol hydrochloride (AY-23,028) is the antagonist for adrenergic receptor and dopamine receptor. (±)-Butaclamol hydrochloride antagonizes amphetamine or Apomorphine (HY-12723)-induced stereotyped behaviors and emesis, inhibits discriminative avoidance behavior, and induces catalepsy in rats models .
loading...
    loading...
Cat. No.: HY-111136
CAS No.: 916898-61-8
BL-1020 mesylate is the mesylate salt form of BL-1020. BL-1020 mesylate is an antipsychotic agent. BL-1020 mesylate is inhibitor for dopamine receptor and serotonin receptor (5-HT receptor), with Ki of 0.066, 0.062 and 0.21 nM, for D2L, D2S and 5-HT2A receptors, respectively. BL-1020 mesylate is agonist for GABAA receptor with Ki of 3.74 μM, and enhances the GABA release. BL-1020 mesylate exhibits high affinity with histamine receptor (Ki is 0.47 nM). BL-1020 mesylate reduces Amphetamine-induced hyperactivity, with lower catalepsy and sedation. BL-1020 mesylate is blood-brain barrier penetrate .
loading...
    loading...
Cat. No.: HY-105704
CAS No.: 31232-26-5
Synonyms: NSC 170955; WA 335
Target:  

5-HT Receptor

Research Areas:  

Neurological Disease

Danitracen (NSC 170955) is an orally active, CNS penetrant serotonin antagonist with antidepressant activity. Danitracen reduces serotonin levels in the cerebrum, cerebellum, medulla and the whole brain. Danitracen exhibits anticataleptic effects in rat catalepsy models. Danitracen can be used for catalepsy and depression research .
loading...
    loading...
Cat. No.: HY-106898A
CAS No.: 136777-43-0
Target:  

5-HT Receptor

Research Areas:  

Neurological Disease

Carvotroline hydrochloride is an antipsychotic agent and 5-HT2 receptor antagonist, with a Ki value of 211 nM for the 5-HT2 receptor. Carvotroline hydrochloride modulates the activity of the stress-related hypothalamic-pituitary-adrenal axis. Carvotroline hydrochloride exerts a stronger blocking effect on Apomorphine (HY-12723)-induced climbing behavior than on Apomorphine-induced stereotyped behavior. Carvotroline hydrochloride inhibits conditioned avoidance responses in rats and monkeys without inducing catalepsy. Carvotroline hydrochloride can be used in studies related to schizophrenia .
loading...
    loading...
Cat. No.: HY-179436
CAS No.: 1781270-07-2
Synonyms: 9β,10β-EHHC; 9β,10β-epoxy HHC
Target:  

Cannabinoid Receptor

Research Areas:  

Neurological Disease

9β,10β-epoxy Hexahydrocannabinol is a cannabinoid receptor 1 (CB1) and CB2 receptor ligand with a binding affinity of 224 nM for CB1 and 335 nM for CB2. 9β,10β-epoxy Hexahydrocannabinol reduces locomotor activity, induces catalepsy, lowers body temperature, and produces antinociceptive effects in mice. 9β,10β-epoxy Hexahydrocannabinol can be used for the study of nervous system diseases .
loading...
    loading...
Cat. No.: HY-182638
CAS No.: 1829530-11-1
Synonyms: CPL500036
Alofropodect is an orally active, blood-brain barrier permeable phosphodiesterase 10A (PDE10A) inhibitor with IC50 values of 1 nM (Reference 1) and 35 nM (Reference 2). Alofropodect acts as a negative allosteric modulator of the M2 muscarinic receptor with an IC50 of 9.2 μM. Alofropodect alters cyclic nucleotide levels in basal ganglia circuits, inhibits the hydrolysis of cAMP and cGMP, and suppresses hERG potassium channel tail currents. Alofropodect induces catalepsy in rats and reverses injury-induced contralateral forelimb use impairment. Alofropodect can be used in research related to schizophrenia, Parkinson's disease, and levodopa-induced dyskinesia .
loading...
    loading...
Cat. No.: HY-108942
CAS No.: 851087-60-0
ASP5854 is an orally active, blood-brain barrier permeable adenosine A1/A2a dual receptor antagonist. ASP5854 blocks receptor activity and agonist-induced intracellular calcium elevation, and exhibits the characteristic of slow dissociation from striatal A2a receptors in primates. ASP5854 reverses catalepsy, enhances cognitive ability, improves motor function and exerts neuroprotective effects, while also alleviating dyskinesia and increasing contralateral turning behavior. ASP5854 is mainly used in studies related to ischemic stroke and Parkinson's disease .
loading...
    loading...
Cat. No.: HY-109139R
CAS No.: 1337962-47-6
Synonyms: NIR178 (Standard); PBF509 (Standard)
Taminadenant (Standard) is the analytical standard of Taminadenant (HY-109139). This product is intended for research and analytical applications. Taminadenant (NIR178; PBF509) is a highly potent and orally active adenosine A2A receptor (A2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparKinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response .
loading...
    loading...
Cat. No.: HY-182381
CAS No.: 84226-14-2
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

FLA-797 is a brain-penetrant dopamine D2 receptor blocker and very low affinity for dopamine D1 receptors. FLA-797 selectively binds to and blocks postsynaptic dopamine D2 receptors. FLA-797 induces catalepsy in male rats. FLA-797 blocks dopamine agonist-induced hypothermia in male rats. FLA-797 contributes marginally to the dopamine D2 receptor-blocking activity of Remoxipride (HY-101313) in male rats. FLA-797 does not mimic the atypical antipsychotic profile of Remoxipride. FLA-797 can be used for research on mental disorders .
loading...
    loading...
Cat. No.: HY-18654A
Target:  

mGluR

Research Areas:  

Neurological Disease

ADX88178 TFA is an orally active, blood-brain barrier-penetrant, selective positive allosteric modulator of mGluR4, with an EC50 of 3.5 nM against hmGluR4. ADX88178 TFA modulates mGlu4 activity, enhances glutamate-mediated receptor activation, and increases the apparent affinity of glutamate for the receptor. ADX88178 TFA reverses haloperidol-induced catalepsy, potentiates the effects of levodopa (L-DOPA) and quinpirole, but fails to alleviate established abnormal involuntary movements, does not exacerbate L-DOPA-induced dyskinesia, and does not affect forelimb akinesia when administered alone. ADX88178 TFA can be used in research related to L-DOPA-induced dyskinesia and Parkinson's disease .
loading...
    loading...